Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

Disease relapse occurs in 50% or more of patients who are autografted for relapsed or refractory lymphoma (NHL) or Hodgkin's disease (HD). The administration of non-cross-resistant therapies during the post-transplant phase could possibly control residual disease and delay or prevent its progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Rapoport, AP, Meisenberg, B, Sarkodee-Adoo, C, Fassas, A, Frankel, SR, Mookerjee, B, Takebe, N, Fenton, R, Heyman, M, Badros, A, Kennedy, A, Jacobs, M, Hudes, R, Ruehle, K, Smith, R, Kight, L, Chambers, S, MacFadden, M, Cottler-Fox, M, Chen, T, Phillips, G, Tricot, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2002
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091694/
https://www.ncbi.nlm.nih.gov/pubmed/11896427
http://dx.doi.org/10.1038/sj.bmt.1703363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091694/
https://www.ncbi.nlm.nih.gov/pubmed/11896427
http://dx.doi.org/10.1038/sj.bmt.1703363

Ejemplares similares